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Sllmmal"y 
The nonobese diabetic (NOD) mouse strain provides a model system for human autoimmune 
diabetes. This disease model is extensively used not only to examine the etiology and pathogenesis 
of diabetes,  but also as a means to evaluate therapies. In NOD mice, the disease progresses from 
insulitis to islet destruction and clinical diabetes in a high percentage of female mice. In this 
study, androgen therapy, begun after the onset of insulitis, was found to prevent islet destruction 
and diabetes without eliminating the islet inflammation in female NOD mice. However, diabetes 
can be adoptively transferred into such hormone-treated recipients. The prevention of disease 
onset by androgen is likely due to the hormonal alteration of the development or function of 
the immune cells necessary for islet  destruction. 
T 
he alleviation of pathogenic autoimmune responses is 
an objective not only in the quest to relieve the suffering of 
those afflicted by the range of autoimmune diseases, but also 
to help understand the basic pathogenic mechanisms leading 
to autoimmunity. In experimental animal models of autoim- 
munity, a great variety of exogenous substances have been 
used therapeutically to  alter autoimmune interactions,  in- 
duding antibodies, immunosuppressive drugs and viruses. One 
of the most extensively utilized models for the study of au- 
toimmunity is the nonobese diabetic (NOD) mouse strain. 
NOD  mice provide an animal model of human type I 
(juvenile-type or insulin-dependent) diabetes mellitus (1). In 
humans, insulitis (an inflammatory infiltrate involving the 
pancreatic islets of Langerhans) is found in recent-onset dia- 
betics. In general, most NOD mice have insulitis by 5-6 wk 
of age. The inflammation is at first periductal, and then sur- 
rounds and infiltrates the islets, after which clinical diabetes 
develops.  The spontaneous inflammatory diabetes that de- 
velops in NOD mice appears to be due to cell-mediated im- 
munity. Disease can be prevented by genetic or physical removal 
of the thymus (2,  3), by treatment with anti-Thy-1  (4)  or 
anti-CD4 antibodies (5), or by therapy with cyclosporin A 
(6). The inflammatory infiltrate is pleomorphic in nature (7). 
Adoptive transfer experiments have revealed that T cells can 
transfer disease (8) and that macrophages are essential to patho- 
genesis (9), but that islet-cell  destruction does not require 
B cells  (10). 
Overt diabetes occurs in most female mice beginning at 
3 mo of age. Although insulitis is present in male NOD mice, 
less than half of these mice progress to diabetes.  A role for 
sex steroids in this sexual dimorphism is likely.  Castration 
of male mice raises their incidence of diabetes, and oopherec- 
tomy of females decreases the progression to diabetes (11, 12). 
However, in the NOD strain, direct effects of steroid hor- 
mones on disease have not been directly examined. This is 
in contrast with another extensively studied animal model 
of autoimmunity, the F1 hybrid between NZB and NZW 
mice. Such B  x  W  mice develop a disease resembling human 
systemic lupus erythematosus, and in this model, female mice 
suffer from a more severe disease than do male mice. In these 
mice, estrogen has an accelerating effect on the humoral-based 
autoimmunity, whereas testosterone improves survival from 
the disease  (13). 
Androgens (testosterone and its more potent metabolite, 
5c~-dihydrotestosterone  [dhT]) have a beneficial effect not only 
on the B  x  W  autoimmune disease, but on other unrelated 
models, such as autoimmune thyroiditis in chickens (14). De- 
spite their beneficial actions on autoimmunity, little is known 
about the actions of androgen on the immune system. Only 
immature cells types in the immune system have been shown 
to express androgen receptors and therefore be candidates for 
androgen effects (15,  16), suggesting that androgens affect 
the precursors of the effector cells. 
The present study was undertaken to examine whether 
androgens may have a protective role in the autoimmune dia- 
betes of NOD mice. These studies demonstrate that the hor- 
mone indeed has a profound effect: dhT prevents the devel- 
opment of diabetes. Adoptive transfer experiments reveal that 
this sex steroid likely acts to prevent the development or per- 
petuation of a destruction immune attack on the pancreatic 
3  cells. 
Materials  and Methods 
Animals.  Female  NOD/Shi mice were obtained from the ro- 
dent breeding facility at The Scripps Research Institute. Mice were 
1409  J.  Exp. Med. @ The Rockefeller University Press ￿9 0022-1007/92/05/1409/04  $2.00 
Volume 175  May 1992  1409-1412 maintained in microisolator  cages under specific  pathogen-free  con- 
ditions. Glucose determinations were made using a drop of retro- 
orbital  sinus blood  obtained from  mice under  methoxyflurane 
anesthesia. The blood was reacted with Chemstrip bG and glucose 
concentrations  read on an AccuChek  II monitor following  manufac- 
turer's (Boehringer Mannheim Diagnostics, Indianapolis, IN) in- 
structions. Diabetes was defined  as a blood glucose  reading of >400 
mg/dl. 
Sex Steroid Thera~.  Hormone treatment consisted of subcuta- 
neous implantation of pellets (Innovative Research of America, 
Toledo, OH) containing 15 mg of dhT released over a 60-d period, 
designed to yield plasma dhT levels of 5-10 ng/ml (17-34 nM). 
Control mice received pellets containing the carrier-binder alone. 
Pellets were placed in mice receiving methoxyflurane anesthesia, 
and were first implanted when mice were 51-61 d old, and repeated 
at 60-d intervals. 
Adoptive Transfer.  Eight recipient mice each received  a hormone 
pellet a 51-57 d of age, and were prepared for adoptive transfer 
of cells at 61-68 d of age (8-11 days after the onset of hormone 
treatment) by whole body irradiation from a cesium source using 
775 tad. The mice were then given an intravenous injection con- 
taining 1-1.5  x  107 spleen cells, prepared from untreated diabetic 
NOD female mice. Blood glucose levels were measured at least 
twice in the next 4 wk. 
Histology.  Pancreata were removed from killed animals, fixed 
for 4 h in Bouin's  fixative,  transferred  to 70% ethanol, and processed 
for paraffin embedding. Tissue sections were stained with hema- 
toxylin and eosin, and three different levels sections were examined 
from each specimen. For immunohistology,  unstained sections  were 
depara~nized,  incubated in 0.1 M glycine to quench aldehydes, 
blocked in 2% goat serum, then reacted sequentially with guinea 
pig antiinsulin (1/300 dilution) and biotinylated goat anti-guinea 
pig (1/200 dilution) antibodies. Sections were then reacted with 
hydrogen peroxide/methanol to block endogenous peroxidase ac- 
tivity, and then incubated with avidin-biotin-horseradish  peroxi- 
dase complex. Antibodies and avidin-biotin-horseradish  peroxidase 
complex were obtained from Vector Laboratories,  Inc. (Burlingame, 
CA). The peroxidase was developed using 3,3'-diaminobenzidine 
as a chromogen in the presence of hydrogen peroxide and nickel 
chloride, and sections  were lightly counterstained  with methyl green. 
Results and Discussion 
Both male and female NOD mice develop  insulitis, but 
only a high percent of female mice progress to clinical dia- 
betes.  To determine whether part of this effect may be due 
to androgenic hormones, dhT treatment of female NOD mice 
was begun. Therapy with dhT was chosen to insure the pres- 
ence of this more potent form of androgen in the tissues, 
and  to  prevent  the  possible  peripheral  aromitization  of 
testosterone to estrogen. 
Beginning at "~8 wk of age, pellets containing dhT, or con- 
trol pellets lacking the hormone, were implanted subcutane- 
ously into NOD mice. Most control mice, as expected, de- 
veloped clinical diabetes (Fig. 1), yet none of the dhT-treated 
animals, followed to 31 wk of age, became diabetic.  Average 
blood glucose values (+  SD) from this treated group ranged 
from 144 (_+  14) mg/dl to 162 (_+  38) mg/dl, only slightly 
higher than those found in C57BL/6J mice maintained under 
similar conditions (138 [+  20]  mg/dl). 
Since insulitis precedes the onset of diabetes,  one mecha- 
nism by which dhT may prevent diabetes  is by eliminating 
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Figure 1.  Androgen  treatment  prevents the onset of diabetes in NOD 
mice. The percentage of mice with clinical  diabetes is indicated  for the 
two treatment groups: Placebo treated (@) and dhT treated (O). Blood 
glucoses were measured  biweekly;  values  >400 mg/dl  were defined  as dia- 
betic since animals with such blood glucose readings had clinical signs 
of diabetes, such as polydipsia,  polyuria,  and weight loss. Eight mice re- 
ceived 60-d release control or dhT-containing  pellets at the onset of the 
study and new pellets were given twice at the end of the 60-d interval. 
One dhT-treated  mouse  lost its hormone  pellet and was killed  before the 
conclusion of the study. 
or reducing the inflammatory infiltrate in the islets. Histo- 
logical examination of the pancreata from female NOD mice 
at 8 wk of age, when the hormone treatment began, revealed 
the presence of islets with inflammatory infiltrates of varying 
degree, and evidence of destructive lesions (Fig. 2, A and B). 
Analysis of the pancreata from 31-wk-old dhT-treated  mice 
revealed the continued presence of insulitis, ranging from le- 
sions with minimal inflammation to islets with destructive 
lesions (Fig. 2, C and D). In these mice, the islets of Langer- 
hans were easily identifiable.  This is in contrast to the con- 
trol group, killed after the onset of diabetes,  in which only 
atrophic islets can be identified, with some showing residual 
inflammation  (Fig.  2  E).  Immunohistochemical analysis 
confirmed  the  presence  of islets  with  abundant  insulin- 
containing B cells in the pancreata of hormone-treated animals 
(Fig.  2 F) and their absence in control mice. 
There are two distinct classes of mechanisms by which dhT 
may be preventing the B cell death. First, the effect may be 
on the immune system, preventing the killing of the B cells 
by eliminating, inactivating, or altering the functional prop- 
erties of the cells necessary for the self destruction. Second, 
the effect may be on nonimmune cell types, such as on the 
endothelium to prevent trafficking of certain immune cells 
into the islet,  or on the B cell itself to protect it from im- 
mune attack. 
Adoptive transfer experiments were performed to attempt 
to distinguish between these possibilities.  In NOD  mice, 
transfer of spleen cells from diabetic animals into young, ir- 
radiated recipients leads to an acceleration  of disease in the 
recipients (17). Young dhT-treated female mice received spleen 
cells from older, diabetic female mice, and the recipients were 
monitored for the onset of diabetes.  As shown above, dhT- 
treated mice did not become diabetic by at least  31 wk of 
age. In contrast, all dhT-treated mice receiving diabetic spleen 
cells became diabetic by 13 wk of age (4 wk after transfer). 
1410  Androgen  Prevents Diabetes in Nonobese Diabetic Mice Figure 2.  Iqistopathology of control and dhT-treated NOD mouse pancreata.  (/1 and B) Hematoxylin and eosin-stained pancreatic sections  from 
8-wk-old mice (x 77 and  x 83). Inflammatory infiltration of the islets and islet cell destruction is already present in mice of this age. (C and D) Hematox- 
ylin and eosin-stained pancreatic  sections  from 31-wk-old, dhT-treated mice (x83).  Varying degrees  of inflammation are present in these mice.  (E) 
Hematoxylin and eosin-stained pancreatic section from a 22-wk-old placebo-treated mouse (x 128). Remaining islets contain a paucity of cells, and 
some still show inflammation. (F) Immunoperoxidase staining for insulin in islet of a 31-wk-old,  dhT-treated female mouse (x95). Islets in dhT-treated 
mice contain abundant immunoreactive insulin in B cells. 
Pretransfer blood levels averaged 141 (_+ 19) mg/dl, whereas 
after transfer blood glucose levels  were diagnostic of diabetes, 
445 (_+  17) mg/dl. Similarly manipulated dhT-treated mice 
receiving control spleen cells (from young, nondiabetic fe- 
male NOD mice) did not become diabetic in this period. 
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These adoptive transfer experiments reveal  that spleen ceils 
from a diabetic animal are capable of  inducing disease  in dhT- 
treated recipients. Therefore, dhT cannot be acting to pro- 
tect the/5 cell itself from damage, by preventing the infiltra- 
tion of specific  pathogenic cells  into the islets, or by inhibiting effector cells that have developed in nontreated animals.  In 
dhT-treated mice, the progression of the immune cell attack 
is blocked. 
The identity of the cell type(s) affected by androgen therapy 
remains unknown. However, a synergistic effect of thymec- 
tomy with castration was found to increase diabetes in male 
NOD mice (12). Given the presence of androgen receptors 
in thymocytes (15), the thymus is a potential target for dhT, 
affecting T  cell differentiation and function. Since the mo- 
lecular mechanisms by which steroid hormones exert their 
effects is becoming increasingly elucidated, this system should 
be fruitful to unravel the pathway responsible for the protec- 
tive effect of androgens on autoimmunity. 
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